Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease.
about
Design of universal cancer vaccines using natural tumor vessel-specific antigens (SANTAVAC)Evidence of the extrathymic development of tyrosinase-related protein-2-recognizing CD8+ T cells with low avidityGeneration in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysateLabel-free cytokine micro- and nano-biosensing towards personalized medicine of systemic inflammatory disordersIdentification and characterization of 9D7, a novel human protein overexpressed in renal cell carcinoma.Proteomics in cancer vaccine development.SANTAVAC ™: A Novel Universal Antigen Composition for Developing Cancer Vaccines.Heat-shocked tumor cell lysate-pulsed dendritic cells induce effective anti-tumor immune response in vivo.Future therapeutic targets in rheumatoid arthritis?Progress in cancer vaccines by enhanced self-presentationRemnants of suicidal cells fostering systemic autoaggression. Apoptosis in the origin and maintenance of autoimmunity.Dendritic cell-specific antigen delivery by coronavirus vaccine vectors induces long-lasting protective antiviral and antitumor immunity.Immunotherapy: on the edge between experimental and clinical oncology.Biologic and therapeutic role of HER2 in cancer.Tumor-induced endothelial cell surface heterogeneity directly affects endothelial cell escape from a cell-mediated immune response in vitro.Universal cancer vaccine: an update on the design of cancer vaccines generated from endothelial cells.Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now?Vaccines in oncology: background and clinical potential.Cell-based therapy approaches using dying cells: from tumour immunotherapy to transplantation tolerance induction.Generation of dendritic cell-based vaccines for cancer therapy.An autoimmune-mediated strategy for prophylactic breast cancer vaccination.Towards patient-specific tumor antigen selection for vaccination.Genetically modified dendritic cells--a new, promising cancer treatment strategy?Dendritic cell-based vaccines and therapies for cancer.Principles of tumor immunosurveillance and implications for immunotherapy.Cancer immunotherapy: the past, the present and the future.Dendritic cell-based immunotherapy for the treatment of hematological malignancies.Tumor antigens and proteomics from the point of view of the major histocompatibility complex peptides.Immunotherapy exploiting the versatility of dendritic cells.Dendritic cells and their potential therapeutic role in haematological malignancy.Autoimmune mediated regulation of ovarian tumor growth.Linking immune-mediated arterial inflammation and cholesterol-induced atherosclerosis in a transgenic mouse model.MHC-bound antigens and proteomics for novel target discovery.Progress in the development of immunotherapy of cancer using ex vivo-generated dendritic cells expressing multiple tumor antigen epitopes.Broadly expressed tumour-associated proteins as targets for cytotoxic T lymphocyte-based cancer immunotherapy.Immunoprevention of basal cell carcinomas with recombinant hedgehog-interacting protein.Dendritic cells loaded with apoptotic antibody-coated tumor cells provide protective immunity against B-cell lymphoma in vivoAdministration route-dependent vaccine efficiency of murine dendritic cells pulsed with antigens.Evaluation of the Effect of the 47 kDa Protein Isolated from Aged Garlic Extract on Dendritic Cells.Cytotoxic T cells induce proliferation of chronic myeloid leukemia stem cells by secreting interferon-γ.
P2860
Q28087470-68F7AB8B-F2FA-4474-BD62-4C9D3C7CE10EQ28360452-D1DE4C03-7DE6-47D3-8A00-95A921FA0DA2Q28362580-CE112ADF-A77A-4AE0-95C9-2EC542F26B88Q30368512-8C0FA13B-3908-4CBB-999C-0EE5C7F236B1Q30790800-6803642E-1462-4428-A50E-916B9C0247C8Q33215044-F6B67AFC-422D-4C1F-8CD7-6AB0E08BB34BQ33578086-3E9FF3EC-B4C0-415A-A7BB-410ABD113BD7Q33788255-01BA6985-D9F6-44EF-9F08-BEA96C222445Q33841419-2DAE877C-1296-4BB2-81E1-C863B592E335Q33929076-60B49A56-01E0-49A6-8B76-DCBCE0900353Q34004618-245F061B-DA87-496D-9C0D-A7178C747DD2Q34128906-84297B60-839F-4749-A5AC-72168A8DDBBEQ34172095-7BB08F35-C405-4D51-9AF0-635887A4CFB7Q34267775-E1AE4FD8-A669-436D-9E88-ABFB6F31C8D3Q34329922-77691C87-6607-4FCF-BF93-10CF126B698AQ34338192-10022EE3-2589-478C-84D3-EF83294558B1Q34338355-44F30721-FA03-4F94-954F-8CC274C2D1E4Q34439914-0655BB5A-AB85-4D2C-B426-C8E3E35BEF38Q34560654-794EC2D4-E482-4593-9870-C0369AC6C8BCQ34708252-9D3366F9-B09F-492F-9E56-53CACE8F1F12Q34985115-E13894CF-526E-4C2A-A110-AC9931EC0EB0Q35005960-52D8A3E1-E227-49EA-B7A1-4F42FF2C3D8CQ35040829-60C1A602-2899-4242-B68E-A121CADD99BDQ35040857-FDEA6ADF-7878-4E2E-9F30-1F2CE3DB6673Q35043113-9C667B16-B806-4983-8791-ABE596FB977CQ35083647-CF9A1330-D0F6-483B-991D-0776C8879EB0Q35127001-B282054A-0661-40BA-AC46-AD3861D0761DQ35160569-958F31B9-E541-41AD-B5C2-E7B2F0F67EC5Q35201914-E97EC19A-2164-42EE-B027-BF8DE3BE2D5FQ35614625-C93CD411-E48F-46DC-8F2C-F5D7D41B97C3Q35673346-D6E4AA9A-FEC2-48CB-BFA9-35A0F23E94B2Q35824235-E6BA2A7F-C1E4-499C-A5BC-0A398E3B7C97Q35911151-852A5B7C-6C11-4DC7-9091-C7BA2F450025Q35922431-1BDF4E70-40D8-4AD1-8AB2-5F03EB19A78CQ36239656-344FBAAA-124E-45EE-AE4B-92818FEB913FQ36402362-DF8EFB4F-3F95-45F4-B8EF-6332CD469B29Q36407174-E7A35AF5-7867-43C9-A697-3C7E6A5DD911Q36622359-0560FC5E-E75B-483B-A713-AEC7237BD595Q36652557-47822667-0372-4643-A9C0-422B07B92545Q36694195-33086007-4F55-4A22-A4CB-D0A7202CBA6E
P2860
Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease.
description
2000 nî lūn-bûn
@nan
2000年の論文
@ja
2000年学术文章
@wuu
2000年学术文章
@zh-cn
2000年学术文章
@zh-hans
2000年学术文章
@zh-my
2000年学术文章
@zh-sg
2000年學術文章
@yue
2000年學術文章
@zh
2000年學術文章
@zh-hant
name
Immunotherapy with dendritic c ...... in severe autoimmune disease.
@ast
Immunotherapy with dendritic c ...... in severe autoimmune disease.
@en
type
label
Immunotherapy with dendritic c ...... in severe autoimmune disease.
@ast
Immunotherapy with dendritic c ...... in severe autoimmune disease.
@en
prefLabel
Immunotherapy with dendritic c ...... in severe autoimmune disease.
@ast
Immunotherapy with dendritic c ...... in severe autoimmune disease.
@en
P2093
P2860
P356
P1476
Immunotherapy with dendritic c ...... in severe autoimmune disease.
@en
P2093
Hengartner H
Ochsenbein AF
Odermatt B
Zinkernagel RM
P2860
P304
P356
10.1084/JEM.191.5.795
P407
P577
2000-03-01T00:00:00Z